The disease progression and rate of cancer death were analyzed in 52 patients with stage A prostate cancer who underwent transurethral resection of the prostate (TURP) or retropubic subcapsular prostatectomy (SCP) between 1987 and 1998. We performed immunohistochemistry on 16 patients to determine the correlation between the expression of the tumor metastasis suppressor gene KAI1 and the subsequent progression of stage A prostate cancer. Nineteen and 33 of the patients had cancer at stage A1 and stage A2, respectively, and their subsequent courses were followed for an average of 53.7 months (24 -134 months). Progression to clinical cancer was found in six patients (one with stage A1, and five with stage A2). This progression was evident 40.8 months (5 -80 months) after TURP or SCP. Four (66.7%) of the patients died of cancer progression (average 31 months) after prostatectomy. All four patients had stage A2, poorly differentiated adenocarcinoma, and had been followed with administration of diethylstilbestrol diphosphate (DES-P). The disease-free patients (n ¼ 10) showed overexpression of KAI1 protein, compared to those with disease progression (n ¼ 6). These results indicate that progression arose mainly in the patients with stage A2 cancer, and that poorly differentiated, focal and weak expression of KAI1 protein is highly associated with disease progression. It is suggested that patients in this group should be treated with immediate total androgen blockade, radiation, or radical prostatectomy after diagnosis. Prostate Cancer and Prostatic Diseases (2001) 4, 150-153.
Introduction
For men living in Western countries and Japan, prostate cancer has become the most commonly diagnosed invasive cancer, and the second most frequent cause of cancer death. 1 Most investigators believe that this dramatic rise in incidence of prostate cancer is due to enhanced diagnostic capability and the implementation of communitybased screening programs. 2 Stage A prostate cancer reportedly is present in approximately 2 -21% (average 6%) of patients undergoing transurethral resection of the prostate (TURP) or subcapsular prostatectomy (SCP) for benign prostatic hyperplasia. 3, 4 In the present study, stage A prostate cancer was found in 4.0% of surgical specimens obtained during TURP, and in 5.8% by SCP. Moreover, the incidence rate gradually increased to 25 -40% in step sections. At stage A prostate cancer, the choice of therapy is between radical prostatectomy, endocrine therapy, or radiation therapy, and no treatment is implemented until progression occurs. Beyer et al reported that although only 10% of incidentally discovered lesions progress, the proper management of these stage A lesions remained unclear. 5 It seems to be important to investigate the factors involved in the progression to clinical cancer which account for differences in the prostate cancer mortality rates around the world.
KAI1 is a tumor metastasis suppressor gene that is capable of inhibiting the metastatic process in animals. The immunohistochemical analysis of human tumor samples revealed that the expression of KAI1 in most cases is down-regulated during the tumor progression of not only prostate 6, 7 but also of lung, 8 breast, 9 bladder, 10 and pancreatic 11 cancers. We examined the expression of KAI1 protein to determine its value in predicting the risk of disease progression in patients with incidentally discovered prostate cancer.
Materials and methods

Patients and samples
Out of a total of 350 cases of prostate cancer seen at Nagoya City University Medical School between 1987 and 1998, 52 patients were diagnosed with stage A prostate cancer which was subdivided into stage A1 (19 patients) and A2 (33 patients), according to the Whitmore -Jewett classification (General Rules for Clinical and Pathological Studies on Prostate Cancer in Japan). 12 The prognosis of all stage A patients was evaluated in April 1999. The interval between initial surgery and follow-up was 24 -134 months (mean: 53.7 months).
Disease progression was defined as symptomatic local recurrence or the appearance of metastatic disease. Elevation of the prostatic acid phosphatase or prostate specific antigen level alone was not considered sufficient to classify the patient as having progressive disease.
Immunohistochemistry
Paraffin-embedded tissue sections obtained from 10 disease-free patients (six had poorly, two moderately and two well-differentiated adenocarcinoma) and six patients with disease progression (five had poorly and one well-differentiated adenocarcinoma), were dewaxed in Histochoice Cleaning Solution (Amresco, Ohio), rehydrated in a graded series of ethanol (100, 95, 70, and 50%) and washed in distilled water. Endogenous peroxidase activity was quenched in 1.5% H 2 O 2 /PBS (Sigma, St. Louis, MO, USA) for 15 min followed by washing twice with PBS. Non-specific protein binding was blocked in casein wash buffer (0.3% casein/0.5% Tween 20/PBS) for 30 min. Sections were then incubated for 1 h at room temperature with the primary antibody, (polyclonal anti-KAI1 antibody, a gift from Prof PJ Russell, New South Wales University, NSW, Australia), washed twice in 1:10 casein wash buffer for 5 min, and then incubated with 1:250 biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA) for 30 min. Specific intracellular immunoreactivity was detected by incubation with avidin-biotin/ horse radish peroxidase complex (Vector Laboratories, Burlingame, CA, USA) for 45 min at room temperature followed by color development in 0.05% diaminobenzidine/0.01% H 2 O 2 /PBS pH7.6 chromogen (Sigma, St. Louis, MO, USA) for 5 min. Color development was stopped by washing in distilled water, and sections were lightly counterstained in hematoxylin, dehydrated in a graded series of alcohol, cleared in xylene, and finally mounted in Eukitt.
Semiquantitative analysis 13
Immunoreactivity was assessed on a scale of 0 -4 as follows: no staining (0); focal, weak staining (1); strong staining of 25% or moderate staining of < 80% (2); strong staining of 25% to 50% or moderate staining of > 80% (3); strong staining of > 50% tumor cells (4) .
Statistical analysis
The results of therapy were analyzed according to age and clinical stage by the Kaplan -Meier method for calculating the mean or median for time to progression. 14 The statistical significance of differences was tested by the generalized Wilcoxon test. Student's t-test was used for statistical comparisons between the two groups.
Results
The age of the patient at diagnosis ranged from 52 -89 y ( Table 1 ). Diagnosis was made by TURP in 45 patients and by SCP in seven. In all patients, the complaints were related to voiding dysfunction, with obstructive or irritative symptoms occurring in nearly equal numbers of patients.
Most attempts to subclassify stage A prostate cancer have centered around histopathological staging, evaluating the grade or degree of differentiation and the percentage of tissue volume involved by the tumor. We used the Whitmore -Jewett classification (General Rules for Clinical and Pathological Studies on Prostate Cancer in Japan 12 ).
The average weight of tissue resected by TURP or SCP was similar in stage A1 and A2 patients, 12.2 g and 15.4 g, respectively, in TURP, and 50.0 g and 61.0 g in SCP. Thus, the frequency of stage A prostate cancer was not related to the weight of the prostate tissue resected. However, the average weight of prostatic tissue in the patients with disease progression was significantly smaller 9.8 g, than in those tumor-free (P < 0.05). Of the patients with stage A1 disease, 31.6% did not receive any anti-cancer treatment until progression appeared, and the remaining patients received endocrine therapy. Approximately 90.9% of stage A2 patients were treated with endocrine therapy, radical prostatectomy, or a combination of the two. The other 9.1% were followed without any treatment (Table 2) .
Cause-specific survival varied widely, from less than 1 y to a maximum of 8.0 y. Of the stage A2 patients 83.3% showing disease progression had poorly differentiated adenocarcinoma, indicating that the patients with less differentiated carcinoma exhibited a tendency towards progression. Five of the patients with disease progression (83.3%) had received endocrine therapy, especially administration of DES-P (Table 3) . Analysis by the Kaplan -Meier method revealed no difference between A1 and A2 patients without disease progression, but (Figures 1 and 2) . The results of the immunohistostaining of the specimens from the disease-free patients and those with disease progression are presented in Table 4 . Immunoreactivity to KAI1 was a statistically significant predictor of disease progression in the patients with stage A prostate cancer. Furthermore, in the disease-free group, KAI1 expression correlated with the Gleason score (sum) (Figure 3 ).
Discussion
The optimal therapy for management of stage A carcinoma with a high probability of progression has not been established clearly. Since the possibility of recurrence in stage A1 prostate cancer is not a strong, observation of the clinical course without any treatment is generally accepted. However, in our series, a stage A1 case without any treatment progressed to clinical cancer 56 months after surgery for benign prostatic hyperplasia. Blute et al reported that 27% of stage A1 cases progressed to clinical cancer during long-term (average: 10.2 y) follow-up. 15 The present study is in agreement with their report, and stage A1 patients, especially young patients, need to be observed carefully.
McNeal et al reported that the biological characteristics of prostate cancer at stage A were similar to those at stage B in terms of cancer volume and sub-classification of grade, except for the site of origin. 16 Although this does not agree with the findings we obtained in the present study, the fact that stage A2 cancer contains cancer cells with a variety of biological properties is of major importance. When these properties are identified and better understood, we will be able to achieve more effective treatment modalities and predict more accurately the subsequent disease course. In patients with stage A2 cancer, especially poorly differentiated carcinoma, and life expectancy longer than 10 y, the aggressive modalities of radical prostatectomy, radiation therapy and interstitial brachy-therapy are curable methods.
The KAI1 gene was isolated originally as a prostatespecific tumor metastasis suppressor gene. 17 The protein has four hydrophobic and presumably transmembrane It appears to function in cell -cell and cellextracellular matrix interaction, thereby potentially influencing the ability of cancer cells to invade tissues and to metastasize. In our data, KAI1 protein expression in the patients with disease progression was significantly lower than that in the disease-free patients. Immunoreactivity to KAI1 will be a statistically significant predictor of the disease progression as well as the Gleason score (sum) in the patients with stage A prostate cancer.
In conclusion, stage A1 cancer progresses after longer intervals from diagnosis and at a lower frequency than stage A2. However, patients with stage A1 disease, especially those with low expression of KAI1 protein even with a high Gleason score are not free from the risk of progression, and this factor must be recognized in the management of young men with stage A1 prostate cancer. Stage A2 patients in a good performance status, especially with poorly differentiated adenocarcinoma, should receive radical prostatectomy or irradiation. We concluded that KAI1 has no advantage over Gleason grade, but may be helpful in predicting disease progression. Furthermore, accurate staging using transrectal ultrasonography, computed tomography and bone scintigraphy is necessary before management for prostate cancer is decided.
